
Sir Jim Ratcliffe, the chair of INEOS, the private chemicals giant, has accused Britain’s competition watchdog of being ‘increasingly hostile to business’, following its rejection of the firm’s $1bn acquisition of Sika AG, a concrete additives business.
Ratcliffe claims the Competition and Markets Authority (CMA) prevented the takeover without having any competing businesses and refused to meet face-to-face in the process. The rejection has seen Sika AG, which employed 1,600 people across the world producing concrete admixtures needed for the construction industry, purchased by a US firm instead.
Speaking out about the decision, Ratcliffe stated, “The latest snub led to Sir Jim Ratcliffe accusing the CMA of ‘building a reputation as an overly aggressive regulator with little regard for the impact of its decisions on UK business.’” He added, “He claimed ‘the CMA and UK government are becoming increasingly hostile to business.’”
Read more: UK CMA Accepts CVS’s Offer To Sell The Vet, Ending Probe
Responding to Ratcliffe’s remarks, a CMA spokesperson offered an explanation for the rejection: “Effective merger control is pro-business and pro-growth… When we conclude a deal can go ahead subject to part of a merged business being sold, we assess, among other criteria, whether potential buyers could lead to further competition problems. It is critical when approving a potential buyer that we don’t allow new competition problems to develop.”
The CMA also pointed to estimates which suggest that during the past 3 years, the CMA merger regime has saved consumers more than £2 billion.
It appears, then, that while Ratcliffe is criticizing the CMA’s decisions, they are only attempting to safeguard both businesses and consumers from the impact of larger mergers that may prevent competition.
Featured News
Judge Orders Apple to Address Fortnite App Block or Face Court Hearing
May 19, 2025 by
CPI
EU Civil Society Groups and Labor Unions Raise Alarm Over Proposed Changes to GDPR
May 19, 2025 by
CPI
EU Antitrust Regulators Push Back Deadline on UniCredit’s Takeover Bid for Banco BPM
May 19, 2025 by
CPI
Intel Challenges €376 Million EU Fine in Ongoing Antitrust Dispute
May 19, 2025 by
CPI
Red Bull Challenges EU Commission Over Lengthy Antitrust Inspection
May 19, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Healthcare Antitrust
May 14, 2025 by
CPI
Healthcare & Antitrust: What to Expect in the New Trump Administration
May 14, 2025 by
Nana Wilberforce, John W O'Toole & Sarah Pugh
Patent Gaming and Disparagement: Commission Fines Teva For Improperly Protecting Its Blockbuster Medicine
May 14, 2025 by
Blaž Višnar, Boris Andrejaš, Apostolos Baltzopoulos, Rieke Kaup, Laura Nistor & Gianluca Vassallo
Strategic Alliances in the Pharma Sector: An EU Competition Law Perspective
May 14, 2025 by
Christian Ritz & Benedikt Weiss
Monopsony Power in the Hospital Labor Market
May 14, 2025 by
Kevin E. Pflum & Christian Salas